The U.S. Court of Appeals for the Federal Circuit (CAFC) today issued a precedential decision reversing a district court’s determination that certain claims of a patent for Novartis’ heart failure drug Entresto were invalid for lack of written description, and affirming a finding that the claims were not shown to be invalid for obviousness, lack of enablement, or indefiniteness. Judge Lourie authored the opinion.

Full Article Available Here